Sanofi
Sanofi is a France-based healthcare firm that develops and markets pharmaceutical drugs and OTC medicines for the treatment of a range of diseases such as diabetes and cancer.
Business Model:
Revenue: $43.4B
Employees: 10,001-999,999
Industries / Tags:
Detailed Sanofi Information
Geographic Data
Address: 54, rue La Boetie
City: Paris
State: île-de-france
Zip: 75008
Country: FR
Financial Info
Stage:
post ipo equity
Raised Last:
$329M
Raised Total:$639M
Social
Metrics
71,327Website Global Rank
1,017,349Website Monthly Traffic
Twitter Followers
Description
Sanofi is a France-based healthcare firm that develops and markets pharmaceutical drugs and OTC medicines for the treatment of a range of diseases such as diabetes and cancer.
Contact Phone:
Contact Email:
Sanofi went public on 7/12/2002 on the NYSE
Listed Exchange:
NYSE
IPO Date:
7/12/2002
Ticker Symbol:
SNY
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2021 | Owkin | Corporate Round | 0 |
| 1/2019 | BioNTech | Corporate Round | 91.2M |
| 11/2021 | Gyroscope Therapeutics | Corporate Round | 0 |
| 2/2023 | SwipeRx | Series B | 0 |
| 8/2022 | Innovent Biologics | Post-IPO Equity | 0 |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 1/2022 | Exscientia | Post-IPO Equity | 100M |
| 9/2016 | Onduo | Seed Round | - |
| 10/2014 | Portal Instruments | Series A | 11M |
| 10/2018 | Enable Injections | Series B | 0 |
| 9/2018 | Fulcrum Therapeutics | Series B | 80M |
| 2/2019 | Aetion | Series B | 0 |
| 9/2019 | Veralox Therapeutics | Seed Round | 0 |
| 1/2012 | Warp Drive Bio | Private Equity Round | 125M |
| 8/2014 | MyoKardia | Venture Round | 0 |
| 12/2016 | Eden Biologics | Private Equity Round | 80M |
| 9/2017 | Thermalin | Series A | 17.5M |
| 6/2011 | Esperance Pharmaceuticals | Series B | 0 |
| 2/2021 | Novadiscovery | Series A | 0 |
| 11/2022 | Livmed&s;s | Seed Round | 0 |
| 10/2019 | Icosavax | Series A | 0 |
| 2/2023 | Provention Bio | Post-IPO Equity | 0 |
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 4/2011 | KAHR medical | Venture Round | 3M |
| 10/2018 | Eden Biologics | Post-IPO Equity | - |
| 2/2012 | Melinta Therapeutics | Post-IPO Equity | 3M |
| 2/2023 | Provention Bio | Post-IPO Equity | 0 |
| 2/2023 | SwipeRx | Series B | 0 |
| 11/2022 | Livmed&s;s | Seed Round | 0 |
| 8/2022 | Innovent Biologics | Post-IPO Equity | 0 |
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 11/2021 | Owkin | Corporate Round | 0 |
| 11/2021 | Gyroscope Therapeutics | Corporate Round | 0 |
| 2/2021 | Novadiscovery | Series A | 0 |
| 10/2019 | Icosavax | Series A | 0 |
| 9/2019 | Veralox Therapeutics | Seed Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2022 | Post-IPO Equity | 1 | $329M |
Blackstone Life Sciences Blackstone Life Sciences Blackstone Life Sciences Blackstone Life Sciences |
12/2014 | Post-IPO Equity | 1 | $310M |
Evotec Evotec Evotec Evotec |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 3/2023 | Provention Bio | |
| 12/2021 | Amunix | |
| 12/2021 | Origimm | |
| 9/2021 | Kadmon | |
| 8/2021 | Translate Bio | |
| 4/2021 | Tidal Therapeutics | |
| 1/2021 | Kymab | |
| 11/2020 | Kiadis Pharma | |
| 8/2020 | Principia Biopharma | |
| 12/2019 | Synthorx |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
